Suchergebnisse - "Buti, Maria"

PubPharm (16)

1

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B : a randomised, double-blind, phase 3, multicentre non-inferiority study

enthalten in: The lancet. Gastroenterology & hepatology | 2020

von Lampertico, P. | Buti, M. | Fung, S. | +21

2

Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis : The EXPEDITION-8 trial

enthalten in: Journal of hepatology | 2020

von Brown, R. | Buti, M. | Rodrigues, L. | +19

CommentIn: J Hepatol. 2020 Mar;72(3):389-390. - PMID 31703944

3

96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection

enthalten in: Journal of hepatology | 2018

von Agarwal, K. | Brunetto, M. | Seto, W. | +28

4

Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure

enthalten in: Hepatology (Baltimore, Md.) | 2018

von Poordad, F. | Pol, S. | Asatryan, A. | +17

5

Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B

enthalten in: Gut | 2017

von Bayliss, J. | Yuen, L. | Rosenberg, G. | +17

CommentIn: Gut. 2017 Jul;66(7):1349. - PMID 27797942

6

Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response

enthalten in: PloS one | 2017

von Asselah, T. | Moreno, C. | Sarrazin, C. | +12

7

Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection

enthalten in: Gastroenterology | 2017

von Kwo, P. | Gane, E. | Peng, C. | +15

8

Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection : a randomised, double-blind, phase 3, non-inferiority trial

enthalten in: The lancet. Gastroenterology & hepatology | 2016

von Buti, M. | Gane, E. | Seto, W. | +20

CommentIn: Lancet Gastroenterol Hepatol. 2016 Nov;1(3):174-175. - PMID 28404084

9

An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1)

enthalten in: PloS one | 2016

von Asselah, T. | Moreno, C. | Sarrazin, C. | +11

10

Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years

enthalten in: Hepatology international | 2015

von Buti, M. | Fung, S. | Gane, E. | +12